DE60335679D1 - Tricyclischer Thrombinrezeptorantagonist - Google Patents

Tricyclischer Thrombinrezeptorantagonist

Info

Publication number: DE60335679D1
Authority: DE; Germany
Prior art keywords: receptor antagonist; thrombin receptor; tricyclic thrombin; tricyclic; antagonist
Prior art date: 2002-04-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60335679T

Other languages

English (en)

Inventor

Samuel Chackalamannil

William J Greenlee

Yuguang Wang

Yan Xia

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-16

Filing date

2003-04-14

Publication date

2011-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60335679(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-04-14 Application filed by Schering Corp filed Critical Schering Corp

2011-02-17 Application granted granted Critical

2011-02-17 Publication of DE60335679D1 publication Critical patent/DE60335679D1/de

2023-04-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

DE60335679T 2002-04-16 2003-04-14 Tricyclischer Thrombinrezeptorantagonist Expired - Lifetime DE60335679D1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37307202P	2002-04-16	2002-04-16

Publications (1)

Publication Number	Publication Date
DE60335679D1 true DE60335679D1 (de)	2011-02-17

Family

ID=29250954

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE60317493.0T Expired - Lifetime DE60317493T3 (de)	2002-04-16	2003-04-14	Trizyklische thrombin rezeptor antagonisten
DE60331114T Expired - Lifetime DE60331114D1 (de)	2002-04-16	2003-04-14	Trizyklische Thrombinrezeptorantagonisten
DE60335679T Expired - Lifetime DE60335679D1 (de)	2002-04-16	2003-04-14	Tricyclischer Thrombinrezeptorantagonist

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DE60317493.0T Expired - Lifetime DE60317493T3 (de)	2002-04-16	2003-04-14	Trizyklische thrombin rezeptor antagonisten
DE60331114T Expired - Lifetime DE60331114D1 (de)	2002-04-16	2003-04-14	Trizyklische Thrombinrezeptorantagonisten

Country Status (34)

Country	Link
US (3)	US7304078B2 (de)
EP (5)	EP1495018B3 (de)
JP (2)	JP4558331B2 (de)
KR (1)	KR101026929B1 (de)
CN (1)	CN1659162B (de)
AR (1)	AR039570A1 (de)
AT (3)	ATE455774T1 (de)
AU (1)	AU2003221932B2 (de)
BR (1)	BRPI0309309B8 (de)
CA (1)	CA2482858C (de)
CY (3)	CY1107184T1 (de)
DE (3)	DE60317493T3 (de)
DK (2)	DK2065384T3 (de)
EC (1)	ECSP045368A (de)
ES (3)	ES2357876T3 (de)
FR (1)	FR15C0047I2 (de)
HK (3)	HK1070887A1 (de)
IL (1)	IL164585A (de)
LT (1)	LTC1495018I2 (de)
LU (1)	LU92759I2 (de)
MX (1)	MXPA04010308A (de)
MY (1)	MY144040A (de)
NL (1)	NL300746I1 (de)
NO (2)	NO330500B1 (de)
NZ (2)	NZ575139A (de)
PE (1)	PE20040412A1 (de)
PL (1)	PL214718B1 (de)
PT (2)	PT2065384E (de)
RU (2)	RU2329264C9 (de)
SG (1)	SG164279A1 (de)
SI (2)	SI1495018T1 (de)
TW (1)	TWI343919B (de)
WO (1)	WO2003089428A1 (de)
ZA (1)	ZA200408342B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6346510B1 (en)	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
US7488742B2 (en) *	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
US7235567B2 (en) *	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) *	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
US7442712B2 (en) *	2004-05-28	2008-10-28	Schering Corporation	Constrained himbacine analogs as thrombin receptor antagonists
WO2006042017A2 (en) *	2004-10-06	2006-04-20	University Of Rochester	Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US7541471B2 (en) *	2005-01-14	2009-06-02	Schering Corporation	Synthesis of himbacine analogs
US20060172397A1 (en) *	2005-01-14	2006-08-03	Schering Corporation	Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
WO2006076452A2 (en) *	2005-01-14	2006-07-20	Schering Corporation	An exo-selective synthesis of himbacine analogs
DE602006020414D1 (en) *	2005-01-14	2011-04-14	Schering Corp	Synthese von himbacinanaloga
ATE458726T1 (de) *	2005-01-14	2010-03-15	Schering Corp	Exo- und diastereoselektive synthese von himbacin-analoga
WO2006105217A2 (en)	2005-03-31	2006-10-05	Schering Corporation	Spirocyclic thrombin receptor antagonists
WO2007075808A2 (en) *	2005-12-20	2007-07-05	Schering Corporation	Methods for preventing and/or treating a cell proliferative disorder
CN101384259A (zh) *	2005-12-22	2009-03-11	先灵公司	作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂
PE20080183A1 (es) *	2006-04-06	2008-03-10	Schering Corp	Terapias de combinacion de tra
WO2007120730A2 (en)	2006-04-13	2007-10-25	Schering Corporation	Fused ring thrombin receptor antagonists
WO2008005262A1 (en) *	2006-06-29	2008-01-10	Schering Corporation	Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) *	2006-06-30	2012-07-01	Schering Corp	Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) *	2006-06-30	2008-09-17	Schering Corp	Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de)	2006-08-02	2008-02-07	Sanofi-Aventis	Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) *	2006-09-26	2011-06-11	Schering Corp	Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AR063095A1 (es) *	2006-10-04	2008-12-30	Schering Corp	Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina
CN101541782A (zh)	2006-10-04	2009-09-23	先灵公司	作为凝血酶受体拮抗剂的二环和三环衍生物
EP2120879A2 (de) *	2006-12-22	2009-11-25	Schering Corporation	Desintegrationspromoter in nassgranulat-formulierungen mit fester dosierung
US20080234236A1 (en) *	2007-03-23	2008-09-25	Veltri Enrico P	Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
AU2009211888B2 (en)	2008-02-05	2013-06-20	Sanofi	Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments
DK2240487T3 (da)	2008-02-05	2012-04-02	Sanofi Sa	Triazolopyridaziner som para-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
WO2009124103A2 (en) *	2008-04-02	2009-10-08	Schering Corporation	Combination therapies comprising par1 antagonists with par4 antagonists
CA2724430A1 (en)	2008-05-19	2009-11-26	Schering Corporation	Heterocyclic compounds as factor ixa inhibitors
JP5789256B2 (ja)	2009-06-04	2015-10-07	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	トロンビン受容体アンタゴニストの活性代謝物
CA2764172A1 (en)	2009-06-08	2010-12-16	Schering Corporation	A thrombin receptor antagonist and clopidogrel fixed dose tablet
EP2462123B1 (de)	2009-08-04	2013-10-02	Merck Sharp & Dohme Corp.	4,5,6-trisubstituierte pyrimidin- derivate als factor ixa inhibitoren
PL2558462T3 (pl)	2010-04-16	2015-03-31	Sanofi Sa	Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
PL2558465T3 (pl)	2010-04-16	2015-05-29	Sanofi Sa	Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1)
KR101303348B1 (ko)	2010-06-25	2013-09-03	한국화학연구원	트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
WO2013134012A1 (en)	2012-03-06	2013-09-12	Merck Sharp & Dohme Corp.	Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
WO2015013083A1 (en) *	2013-07-22	2015-01-29	Merck Sharp & Dohme Corp.	Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin
US9701669B2 (en)	2013-08-22	2017-07-11	Merck Sharp & Dohme Corp.	Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015026686A1 (en) *	2013-08-22	2015-02-26	Merck Sharp & Dohme Corp.	3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
WO2015026685A1 (en) *	2013-08-22	2015-02-26	Merck Sharp & Dohme Corp.	7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr)	2013-12-16	2016-01-08	Pf Medicament	Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
EP3131897B8 (de)	2014-04-16	2022-08-03	Merck Sharp & Dohme LLC	Faktor-ixa-hemmer
DE102014108210A1 (de)	2014-06-11	2015-12-17	Dietrich Gulba	Rodentizid
CN105985303B (zh) *	2015-02-13	2020-08-14	上海彩迩文生化科技有限公司	抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) *	2015-09-01	2017-03-08	博瑞生物医药（苏州）股份有限公司	沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) *	2015-11-25	2017-05-31	博瑞生物医药（苏州）股份有限公司	一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) *	2016-02-05	2017-08-10	Sanovel Ilac Sanayi Ve Ticaret A.S.	A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) *	2016-02-05	2018-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
TW201738221A (zh) *	2016-04-22	2017-11-01	Jiangsu Tasly Diyi Pharmaceutical Co Ltd	新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
CN106236779A (zh) *	2016-08-22	2016-12-21	孔五	一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr)	2018-12-19	2021-05-07	Cvasthera	Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) *	2019-08-02	2020-06-26	牡丹江医学院	一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) *	2019-10-21	2021-04-22	United States Government as Represented by the Department of Veteran Affairs	Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr)	2020-04-08	2023-04-14	Cvasthera	Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
WO2022018156A1 (en)	2020-07-22	2022-01-27	Janssen Pharmaceutica Nv	Compounds useful as factor xia inhibitors
US11814364B2 (en)	2021-03-18	2023-11-14	Janssen Pharmaceutica Nv	Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en)	2021-03-18	2024-03-05	Janssen Pharmaceutica Nv	Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en)	2021-03-18	2023-12-19	Janssen Pharmaceutica Nv	Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de)	2021-04-06	2022-10-12	BIORoxx GmbH	Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en)	2021-04-30	2024-02-13	Janssen Pharmaceutica Nv	7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en)	2021-07-22	2024-04-16	Janssen Pharmaceutica Nv	Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr)	2022-04-08	2023-10-13	Cvasthera	Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2623810B2 (fr)	1987-02-17	1992-01-24	Sanofi Sa	Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en)	1992-07-30	1999-11-30	Cor Therapeutics Inc	Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en)	1994-01-31	1996-11-19	Elf Sanofi	Method for the secondary prevention of ischemic events
NZ504218A (en) *	1997-11-25	2002-04-26	Schering Corp	Thrombin receptor antagonists
US6063847A (en) *	1997-11-25	2000-05-16	Schering Corporation	Thrombin receptor antagonists
FR2779726B1 (fr)	1998-06-15	2001-05-18	Sanofi Sa	Forme polymorphe de l'hydrogenosulfate de clopidogrel
US7488742B2 (en) *	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
US20040192753A1 (en) *	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
MXPA02012447A (es) *	2000-06-15	2003-04-25	Schering Corp	Antagonistas receptores de trombina.
MY139335A (en)	2001-10-18	2009-09-30	Schering Corp	Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists

2003
- 2003-04-14 WO PCT/US2003/011510 patent/WO2003089428A1/en active Application Filing
- 2003-04-14 DE DE60317493.0T patent/DE60317493T3/de not_active Expired - Lifetime
- 2003-04-14 DK DK09150995.0T patent/DK2065384T3/da active
- 2003-04-14 MX MXPA04010308A patent/MXPA04010308A/es active IP Right Grant
- 2003-04-14 ES ES09150995T patent/ES2357876T3/es not_active Expired - Lifetime
- 2003-04-14 NZ NZ575139A patent/NZ575139A/en not_active IP Right Cessation
- 2003-04-14 CN CN038131129A patent/CN1659162B/zh not_active Expired - Fee Related
- 2003-04-14 CA CA2482858A patent/CA2482858C/en not_active Expired - Lifetime
- 2003-04-14 EP EP03718393A patent/EP1495018B3/de not_active Expired - Lifetime
- 2003-04-14 RU RU2004133375/04A patent/RU2329264C9/ru active
- 2003-04-14 AT AT07016461T patent/ATE455774T1/de not_active IP Right Cessation
- 2003-04-14 NZ NZ535880A patent/NZ535880A/en not_active IP Right Cessation
- 2003-04-14 EP EP09150996A patent/EP2062890B1/de not_active Expired - Lifetime
- 2003-04-14 PT PT09150995T patent/PT2065384E/pt unknown
- 2003-04-14 ES ES07016461T patent/ES2338171T3/es not_active Expired - Lifetime
- 2003-04-14 DE DE60331114T patent/DE60331114D1/de not_active Expired - Lifetime
- 2003-04-14 AR ARP030101302A patent/AR039570A1/es active IP Right Grant
- 2003-04-14 PL PL373332A patent/PL214718B1/pl unknown
- 2003-04-14 SI SI200331110T patent/SI1495018T1/sl unknown
- 2003-04-14 KR KR1020047016409A patent/KR101026929B1/ko active IP Right Grant
- 2003-04-14 ES ES03718393T patent/ES2297150T7/es active Active
- 2003-04-14 PT PT03718393T patent/PT1495018E/pt unknown
- 2003-04-14 EP EP08012015A patent/EP1982984B1/de not_active Expired - Lifetime
- 2003-04-14 PE PE2003000375A patent/PE20040412A1/es active IP Right Grant
- 2003-04-14 BR BRPI0309309A patent/BRPI0309309B8/pt not_active IP Right Cessation
- 2003-04-14 US US10/412,982 patent/US7304078B2/en active Active
- 2003-04-14 EP EP09150995A patent/EP2065384B1/de not_active Expired - Lifetime
- 2003-04-14 DE DE60335679T patent/DE60335679D1/de not_active Expired - Lifetime
- 2003-04-14 AU AU2003221932A patent/AU2003221932B2/en not_active Ceased
- 2003-04-14 AT AT03718393T patent/ATE378330T1/de active
- 2003-04-14 SG SG200607217-7A patent/SG164279A1/en unknown
- 2003-04-14 JP JP2003586149A patent/JP4558331B2/ja not_active Expired - Fee Related
- 2003-04-14 DK DK03718393T patent/DK1495018T3/da active
- 2003-04-14 EP EP07016461A patent/EP1860106B1/de not_active Expired - Lifetime
- 2003-04-14 MY MYPI20031400A patent/MY144040A/en unknown
- 2003-04-14 SI SI200331969T patent/SI2065384T1/sl unknown
- 2003-04-14 AT AT09150995T patent/ATE494284T1/de active
- 2003-04-15 TW TW092108648A patent/TWI343919B/zh not_active IP Right Cessation
2004
- 2004-10-14 IL IL164585A patent/IL164585A/en active IP Right Grant
- 2004-10-14 ZA ZA200408342A patent/ZA200408342B/xx unknown
- 2004-10-15 EC EC2004005368A patent/ECSP045368A/es unknown
- 2004-11-15 NO NO20044963A patent/NO330500B1/no not_active IP Right Cessation
2005
- 2005-04-22 HK HK05103479A patent/HK1070887A1/xx not_active IP Right Cessation
2007
- 2007-04-10 US US11/733,635 patent/US7713999B2/en active Active
- 2007-07-06 US US11/774,358 patent/US20070270439A1/en not_active Abandoned
2008
- 2008-02-07 CY CY20081100152T patent/CY1107184T1/el unknown
- 2008-02-21 RU RU2008106401/04A patent/RU2008106401A/ru not_active Application Discontinuation
2009
- 2009-03-23 HK HK09102736.6A patent/HK1123302A1/xx not_active IP Right Cessation
- 2009-09-14 HK HK09108388.4A patent/HK1129893A1/xx not_active IP Right Cessation
2010
- 2010-03-05 JP JP2010049903A patent/JP2010132710A/ja not_active Withdrawn
2011
- 2011-03-30 CY CY20111100338T patent/CY1111363T1/el unknown
2015
- 2015-06-29 LU LU92759C patent/LU92759I2/xx unknown
- 2015-06-29 NL NL300746C patent/NL300746I1/nl unknown
- 2015-07-01 LT LTPA2015027C patent/LTC1495018I2/lt unknown
- 2015-07-03 FR FR15C0047C patent/FR15C0047I2/fr active Active
- 2015-07-09 NO NO2015016C patent/NO2015016I1/no not_active IP Right Cessation
- 2015-07-10 CY CY2015029C patent/CY2015029I1/el unknown

Also Published As

Publication number	Publication date
SI1495018T1 (sl)	2008-04-30
MXPA04010308A (es)	2005-02-03
NO20044963L (no)	2004-11-15
ECSP045368A (es)	2005-01-03
KR101026929B1 (ko)	2011-04-04
ATE455774T1 (de)	2010-02-15
CA2482858A1 (en)	2003-10-30
BR0309309A (pt)	2005-02-15
NL300746I2 (de)	2016-01-21
DK1495018T3 (da)	2008-02-18
ES2297150T3 (es)	2008-05-01
FR15C0047I2 (fr)	2016-05-06
HK1123302A1 (en)	2009-06-12
RU2004133375A (ru)	2005-07-10
JP4558331B2 (ja)	2010-10-06
IL164585A (en)	2010-11-30
ES2357876T3 (es)	2011-05-03
PT1495018E (pt)	2008-02-19
CY1107184T1 (el)	2012-10-24
AU2003221932B2 (en)	2007-11-22
EP1495018A1 (de)	2005-01-12
NL300746I1 (de)	2016-01-21
RU2329264C2 (ru)	2008-07-20
ATE494284T1 (de)	2011-01-15
KR20040099441A (ko)	2004-11-26
NZ535880A (en)	2007-11-30
CN1659162A (zh)	2005-08-24
SI2065384T1 (sl)	2011-05-31
US7304078B2 (en)	2007-12-04
DE60317493T2 (de)	2008-09-18
EP1982984A2 (de)	2008-10-22
EP1860106B1 (de)	2010-01-20
BRPI0309309B1 (pt)	2018-09-04
EP1495018B1 (de)	2007-11-14
CY2015029I2 (el)	2016-04-13
RU2329264C9 (ru)	2009-04-20
JP2005528406A (ja)	2005-09-22
NO2015016I2 (no)	2015-07-09
US20070179187A1 (en)	2007-08-02
NZ575139A (en)	2010-08-27
EP1982984A3 (de)	2008-10-29
CA2482858C (en)	2010-11-30
SG164279A1 (en)	2010-09-29
ES2297150T7 (es)	2012-03-16
EP2065384A1 (de)	2009-06-03
DE60331114D1 (de)	2010-03-11
AU2003221932A1 (en)	2003-11-03
IL164585A0 (en)	2005-12-18
CN1659162B (zh)	2011-08-31
ATE378330T1 (de)	2007-11-15
DK2065384T3 (da)	2011-05-02
PL214718B1 (pl)	2013-09-30
PE20040412A1 (es)	2004-07-12
LU92759I2 (en)	2015-08-31
AR039570A1 (es)	2005-02-23
CY1111363T1 (el)	2015-08-05
US7713999B2 (en)	2010-05-11
JP2010132710A (ja)	2010-06-17
EP2062890A1 (de)	2009-05-27
WO2003089428A1 (en)	2003-10-30
NO2015016I1 (no)	2015-07-20
US20070270439A1 (en)	2007-11-22
ES2338171T3 (es)	2010-05-04
TW200404068A (en)	2004-03-16
PL373332A1 (en)	2005-08-22
DE60317493D1 (en)	2011-01-13
BRPI0309309B8 (pt)	2021-05-25
CY2015029I1 (el)	2016-04-13
RU2008106401A (ru)	2009-08-27
US20030216437A1 (en)	2003-11-20
EP2062890B1 (de)	2011-01-05
FR15C0047I1 (de)	2015-08-28
EP1495018B3 (de)	2011-03-16
ZA200408342B (en)	2006-05-31
DE60317493T3 (de)	2018-07-12
PT2065384E (pt)	2011-03-16
EP1860106A1 (de)	2007-11-28
EP2065384B1 (de)	2011-01-05
HK1070887A1 (en)	2005-06-30
EP1982984B1 (de)	2013-02-13
TWI343919B (en)	2011-06-21
HK1129893A1 (en)	2009-12-11
NO330500B1 (no)	2011-05-02
LTC1495018I2 (lt)	2017-04-10
MY144040A (en)	2011-07-29

Publication	Publication Date	Title
DE60335679D1 (de)	2011-02-17	Tricyclischer Thrombinrezeptorantagonist
NO20051871D0 (no)	2005-04-18	Opioid reseptorantagonister
DK1682142T3 (da)	2012-10-15	M3-muscarin-acetylcholin-receptor-antagonister
DK1638969T3 (da)	2009-01-26	CGRP-receptorantagonister
IL174538A0 (en)	2006-08-01	Thrombin receptor antagonists
ATE368659T1 (de)	2007-08-15	Thrombinrezeptorantagonisten
ATE525378T1 (de)	2011-10-15	Himbacinanaloga als thrombinrezeptorantagonisten
DK1720859T3 (da)	2010-04-26	Chemokinreceptorantagonister
ATE382034T1 (de)	2008-01-15	Hydroisoindolin-tachykininrezeptorantagonisten
ZA200702790B (en)	2008-09-25	Thrombin receptor antagonists
DE602005009355D1 (de)	2008-10-09	Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
DE60332816D1 (de)	2010-07-15	Nk1-antagonisten
NO20044373L (no)	2004-10-14	Azetidinderivater som CCR-3-reseptorantagonister
DE60328807D1 (de)	2009-09-24	Chimärer antagonist anth1
TH105710B (th)	2011-01-26	โอพิออยด์รีเซปเตอร์แอนตะกอนิสต์
SI1534736T1 (sl)	2010-10-29	Antagonisti Nogo receptorja
DE602004018527D1 (de)	2009-01-29	Furanderivate als ep4-rezeptorantagonisten
SE0003996D0 (sv)	2000-11-01	Receptorantagonister